Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz International GmbH

www.sandoz.com

Latest From Sandoz International GmbH

Sandoz Strikes $500m Deal For GSK Cephalosporins

Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.

Deals Strategy

Stockwatch: J&J And Novartis Fire Opening Salvos Of Earnings Season

J&J’s bullish outlook for 2021, robust fourth quarter and frequent guidance revisions in uncertain times contrasted with Novartis’s reticence.

Stockwatch Sales & Earnings

Sandoz’ Saynor Insists On Value Of ‘Pure Play’ Approach

Sandoz is benefiting from its focus on a “pure play” generics and biosimilars model that is unique among its peers, CEO Richard Saynor tells Generics Bulletin in an exclusive interview.

Strategy Leadership

Biosimilars Boost Offsets Generics Slide For Sandoz

Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.

Sales & Earnings Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register